Seminar | April 9 | 11 a.m.-12 p.m. | 120 Latimer Hall
Soft nucleophilic phosphinocatalysis has been known since the 1960s as a result of the pioneering work of Horner, Price, Rauhut, Currier, and Morita. In the 1990s, Trost and Lu made important discoveries, reporting isomerization, umpolung addition, and [3+2] cycloaddition. Nonetheless, it was not until the 2000s that the area of phosphinocatalysis began to flourish. My group, through careful analysis of the mechanism of the phosphinocatalysis reactions, has demonstrated over two dozen new reactions facilitated by phosphine catalysts. More recent, particularly significant advancement is the creation of chiral phosphines, HypPhos and CarvoPhos, that are derived from a natural amino acid, L-hydroxyproline and (+)/()-carvone, respectively. Their synthetic utility in the phosphine catalyzed annulations, application in total syntheses of (+)-ibophyllidine and ()-actinophyllic acid, and commercialization will be discussed. The phosphinocatalysis reactions that my group has developed have produced structurally varied heterocycles of immense value for numerous practical applications. Examples include the following bio-modulators: (1) inhibitors of the enzymes GGTase‐I and Rab GGTase; (2) an anti-arrhythmic agent (named efsevin) to rescue zebrafish tremblor mutant; (3) an inhibitor (named aplexone) of cholesterol biosynthesis that is more potent than Pfizers Lipitor; (4) compounds inhibiting cell migration and cell invasion; (5) interferon γ‐like compounds that augment innate immune responses of macrophages; (6) inhibitors of cytotoxic T cell lytic granule exocytosis; and (7) inhibitors of serine hydrolases that are specific for platelet-activating factor acetylhydrolases 1b2 and 1b3 (PAFAH1b2/3). Chemical biological studies related with these molecules will be presented during the talk. In addition, recent development in phosphine oxide catalysis research and hydrodealkenylation will also be introduced.
Light refreshments will be served at 10:50 at The Coffee Lab